Company: HRTX
Filing Date: 2025-08-12
Form Type: 8-K
Source: 0000950170-25-107416
Chunk: 5

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-08-12
Form: 8-K
Item: Item 8.01
Chunk 5
---
 convert upon Stockholder Approval into 5,241,410 shares of Common Stock, at a conversion price of $1.50 per share (stated value of $15.00 per share) for an aggregate investment amount of approximately $27.7 million, pursuant to exemptions from registration under Section 4(a)(2) under the Securities Act and/or Rule 506 of Regulation D under the Securities Act (the “ Private Placement,” and together with the Secured Debt Transaction, the Convertible Note Exchange and the Convertible Note Issuance, the “ Refinancing Transactions”).

The Refinancing Transactions closed on August 12, 2025 (the “ Closing Date”).

The foregoing descriptions of the Second Amendment, the Exchange Agreement, the Note Purchase Agreement and the Purchase Agreement do not purport to be complete and is qualified in its entirety by reference to the full text of the Second Amendment, the Exchange Agreement, the Note Purchase Agreement and the Purchase Agreement, which are filed as Exhibits 10.2, 10.3, 10.4 and 10.5 hereto, respectively, and are hereby incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

  Exhibit No.      Description                                                                                                                                                                                           
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
          3.1      Certificate of Designation of Rights, Preferences and Privileges of Series A Convertible Preferred Stock of Heron Therapeutics, Inc.                                                                  
         10.1      Cooperation Agreement, dated August 8, 2025, by and among Heron Therapeutics, Inc. and Rubric Capital Management LP.                                                                                  
         10.2      Second Amendment to Working Capital Facility Agreement, dated August 8, 2025, by and among Heron Therapeutics, Inc., Hercules Capital, Inc., as administrative agent and collateral agent, and th...  
         10.3      Exchange Agreement, dated August 8, 2025, by and among Heron Therapeutics, Inc. and the holders party thereto.                                                                                        
         10.4      Note Purchase Agreement, dated August 8, 2025, by and among Heron Therapeutics, Inc., the purchasers party from time to time thereto and Rubric Capital Management LP.                                
         10.5      Securities Purchase Agreement, dated August 8, 2025, by and among Heron Ther